The Cooper Companies Inc.
Cooper Companies Reports Third Quarter 2025 Financial Results
Summary
On August 27, 2025, The Cooper Companies, Inc. reported its fiscal third-quarter results for 2025. The company's total revenue increased by 6% year-over-year to $1,060.3 million, with CooperVision revenue up 6% and CooperSurgical revenue up 4%. Despite the revenue growth, GAAP diluted earnings per share (EPS) decreased by 6% to $0.49. However, non-GAAP diluted EPS increased by 15% to $1.10. The company also announced an update to its fiscal year 2025 financial guidance, raising its non-GAAP diluted EPS guidance to a range of $4.08 - $4.12.
Profitelligence Alerts
Get alerts for COO
Be first to know when The Cooper Companies Inc. files with the SEC.
Filing Categories
Advertisement
About The Cooper Companies Inc.
The Cooper Companies Inc. is a global healthcare company that specializes in the production of medical devices, prominently focusing on contact lenses and women's health products. As a key player in the healthcare market, Cooper Companies owns two primary business units: CooperVision and CooperSurgical. CooperVision is renowned for its comprehensive range of soft contact lenses, catering to various vision correction needs such as astigmatism, presbyopia, and myopia control. Meanwhile, CooperSurgical provides innovative products and services focused on women's health, from fertility and lab solutions to surgical tools for gynecological procedures. This diversified business model allows Cooper Companies to impact multiple facets of the healthcare industry, supporting healthcare professionals and enhancing patient care. Headquartered in San Ramon, California, The Cooper Companies is significant in advancing optical technologies and essential medical devices, exemplifying growth within the global healthcare and medical device sectors.
Official SEC Documents
Advertisement